REH

human lymphoblastic leukemia cell line (non-T, non-B), derived from ALL patient

Cell Type:
PBMC
Tissue Origin:
blood
Species:
human
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Cell Characteristics:
Suspension

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
R G-009 5e6 30% 70% Plasmid (general) 2 µg 100 µl I/II/2b
R O-009 5e6 47% 50% Plasmid (general) 2 µg 100 µl I/II/2b
R O-013 2e6 67% 90% Plasmid (general) 2 µg 100 µl I/II/2b
R I-009 4e6 68% 50% Plasmid (general) 2 µg 100 µl I/II/2b
R G-009 4e6 55% 69% Plasmid (general) 2 µg 100 µl I/II/2b
SF CA-137 2e5 71-75% 63-67% Plasmid (general) 1 µg 20 µl 4D X-Unit
SF CA-137 1e6 82-86% 57-67% Plasmid (general) 5 µg 100 µl 4D X-Unit

Citations

Categories:
Transfection 
Authors:
Pottier N, Cheok MH, Yang W, Assem M, Tracey L, Obenauer JC, Panetta JC, Relling MV, Evans WE 
In:
Hum Mol Genet (2007) 16(19): 2261-71 
Categories:
Transfection 
Authors:
Leclerc GJ, Leclerc GM, Kinser TT, Barredo JC 
In:
BMC Cancer (2006) 6: 132 
Categories:
Transfection 
Authors:
Lahne HU, Kloster MM, Lefdal S, Blomhoff HK, Naderi S 
In:
Oncogene (2006) 25(17): 2468-76